Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja(Institut Jules Bordet), Andrew Holmes(Frontier Agriculture (United Kingdom)), Martine Piccart(Université Libre de Bruxelles), Eileen Holmes(Frontier Agriculture (United Kingdom)), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Ramona F. Swaby(GlaxoSmithKline (United States)), Michael Untch(Helios Hospital Berlin-Buch), Christian Jackisch(Sana Klinikum Offenbach), István Láng(National Institute of Oncology), Ian Smith(Royal Marsden Hospital), Frances Boyle(University of Sydney), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Carlos H. Barrios(Pontifícia Universidade Católica do Rio Grande do Sul), Edith A. Perez(Mayo Clinic in Florida), Hatem A. Azim(Institut Jules Bordet), Sung‐Bae Kim(Ulsan College), Sherko Küemmel(Kliniken Essen-Mitte), Chiun‐Sheng Huang(National Taiwan University Hospital), Peter Vuylsteke(Clinique Saint-Joseph), Ruey‐Kuen Hsieh(Mackay Memorial Hospital), В. А. Горбунова, Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta), Lydia Dreosti(University of Pretoria), Natalia Tavartkiladze, Richard D. Gelber(Dana-Farber Cancer Institute), Holger Eidtmann, José Baselga(Memorial Sloan Kettering Cancer Center)
Cited by 455
Abstract
Related Papers
No related papers found
Powered by citation graph analysis